Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2025ZDSYLL563-P01 | Other Identifier | Zhongda Hospital Affiliated to Southeast University |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Beijing Hospital of Traditional Chinese Medicine | OTHER |
| The First Affiliated Hospital of Guangzhou Medical University | OTHER |
| Jiangsu Province Hospital of Traditional Chinese Medicine | OTHER |
Not provided
Not provided
Not provided
Not provided
Acute respiratory distress syndrome (ARDS) is a common clinical syndrome in the ICU characterized by extremely high mortality and complex pathogenesis.At present, research on individualized treatment, phenotypic differences, and therapeutic efficacy in ARDS has become a hotspot.As characterized by syndrome differentiation, traditional Chinese medicine (TCM) treatment emphasizes interindividual heterogeneity and personalized management, which is expected to serve as a breakthrough in multi-target immune regulation for ARDS. The primary objective of the study is to investigate the effect of Xuanbai Shengmai Decoction on the prognosis of patients with ARDS in a prospective randomized controlled trial. The secondary objective is to evaluate the safety of Xuanbai Shengmai Decoction in the treatment of patients with ARDS.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control Group | No Intervention | Patients in the control group will receive standard comprehensive Western medical treatment. | |
| Treatment Group | Experimental | Patients in the treatment group will receive Xuanbai Shengmai Decoction via oral administration or nasogastric feeding on the basis of standard comprehensive Western medical treatment. The decoction will be administered within 24 hours after enrollment, one dose per day divided into two administrations, for a total treatment duration of 7 days. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Xuanbai Shengmai Decoction | Drug | Patients in the treatment group will receive Xuanbai Shengmai Decoction orally or via nasogastric gavage on the basis of standard comprehensive Western medical treatment. The decoction will be administered within 24 hours after enrollment, one dose per day in two divided administrations, for a total of 7 days. |
| Measure | Description | Time Frame |
|---|---|---|
| 28-day mortality | Mortality was calculated on day 28 of treatment. | On day 28 of treatment |
| Measure | Description | Time Frame |
|---|---|---|
| Clinical scoring indicator: LIS | Clinical scores were assessed before treatment, on day 3 of treatment, and on day 7 of treatment. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Inflammatory indicator: Interleukin-6 (IL-6,pg/mL) |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Airan Liu, PhD | Contact | +8615295557466 | airanliu@126.com |
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D012128 | Respiratory Distress Syndrome |
| ID | Term |
|---|---|
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D012120 | Respiration Disorders |
Not provided
Not provided
| Subei People's Hospital of Jiangsu Province | OTHER |
| Wuhan Hospital of Traditional Chinese Medicine | OTHER |
| Shenzhen Hospital of Traditional Chinese Medicine | UNKNOWN |
Not provided
Not provided
Not provided
Not provided
|
Serum IL-6 levels (pg/mL) are measured at baseline, Day 3, and Day 7 as a marker of systemic inflammatory response.
| Before treatment,on day 3 of treatment,on day 7 of treatment |
| Pulmonary vascular permeability indicator: Serum angiopoietin-2 (Ang-2,pg/mL) | The concentration of angiopoietin-2 in peripheral blood (pg/mL) will be measured at baseline (pre-treatment), Day 3, and Day 7 of treatment, as a biomarker of pulmonary vascular permeability. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Lung injury indicator:Oxygenation index (PaO₂/FiO₂ ratio) | Arterial blood gas samples will be collected at baseline (pre-treatment), Day 3, and Day 7 of treatment to determine the ratio of arterial partial pressure of oxygen (PaO₂) to the fraction of inspired oxygen (FiO₂), which will be used to assess the patient's oxygenation status. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Ventilator parameter: Tidal volume (VT, mL) | The ventilator-set tidal volume (in mL) will be recorded directly from the ventilator interface at baseline (pre-treatment), Day 3, and Day 7 of treatment. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Duration of mechanical ventilation | Duration of mechanical ventilation within 28 days | within 28 days |
| Length of ICU stay | Time of staying in ICU within 28 days | within 28 days |
| Multiplex detection:Pathogen Load by Multiplex PCR | Throat swabs, fecal samples (10g), and peripheral blood (3mL) will be collected at baseline, day 3, and day 7 of treatment. Multiplex PCR will be performed to detect the nucleic acid load of target pathogens, with the unit of copies/mL, to evaluate changes in infection burden. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Clinical scoring indicator:Acute Physiology and Chronic Health Evaluation Ⅱ (APACHE Ⅱ) score | Assessed using the full APACHE Ⅱ scale at baseline (pre-treatment), Day 3, and Day 7 of treatment. The scale consists of three components: acute physiology score, age score, and chronic health evaluation score, with a total score ranging from 0 to 71. Higher scores indicate greater severity of illness and higher risk of mortality. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Clinical scoring indicators: Sequential Organ Failure Assessment (SOFA) score | Assessed using the full Sequential Organ Failure Assessment scale at baseline (pre-treatment), day 3, and day 7 of treatment. The score evaluates the function of six organ systems: respiratory, coagulation, hepatic, cardiovascular, neurological, and renal, with a total range of 0-24. Higher scores indicate more severe organ dysfunction and a worse prognosis. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Lung injury indicator:Static lung compliance( mL/cmH₂O) | Static lung compliance ( mL/cmH₂O) will be calculated via the ventilator monitoring platform under constant tidal volume and plateau pressure conditions at baseline (pre-treatment), Day 3, and Day 7 of treatment, to assess respiratory mechanics function. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Lung injury indicator:Serum soluble receptor for advanced glycation end products (sRAGE,pg/mL) | Peripheral blood samples will be collected at baseline (pre-treatment), Day 3, and Day 7 of treatment to measure serum sRAGE levels (pg/mL), which serves as a biomarker of pulmonary epithelial injury. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Lung injury indicator:Electrical impedance tomography (EIT) parameters of lung ventilation | Lung ventilation distribution will be monitored by EIT at baseline (pre-treatment), Day 3, and Day 7 of treatment to assess lung injury-related indicators including lung collapse, overdistension, and ventilation inhomogeneity. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Ventilator parameter:Pressure support (PS, cmH₂O) | The pressure support level provided by the ventilator (in cmH₂O) will be recorded directly from the ventilator interface at baseline (pre-treatment), Day 3, and Day 7 of treatment. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Ventilator parameter:Positive end-expiratory pressure (PEEP, cmH₂O) | The positive airway pressure maintained at the end of expiration (in cmH₂O) will be recorded directly from the ventilator interface at baseline (pre-treatment), Day 3, and Day 7 of treatment. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Ventilator parameter:Fraction of inspired oxygen (FiO₂, %) | The fraction of inspired oxygen set on the ventilator (in %) will be recorded directly from the ventilator interface at baseline (pre-treatment), Day 3, and Day 7 of treatment. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Pulmonary vascular permeability indicator: Lung ultrasound B-line score | The number and distribution of B-lines are assessed and scored by lung ultrasound at baseline (pre-treatment), Day 3, and Day 7 of treatment. A higher number and more diffuse distribution of B-lines indicate more severe pulmonary edema. This score is used to evaluate pulmonary vascular permeability and the severity of pulmonary edema. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Inflammatory indicator:Tumor necrosis factor-α (TNF-α,pg/mL) | Serum TNF-α levels (pg/mL) are measured at baseline, Day 3, and Day 7 as a marker of systemic inflammatory response. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Inflammatory indicator:C-reactive protein (CRP,mg/L) | Serum CRP levels (mg/L) are measured at baseline, Day 3, and Day 7 as a marker of systemic inflammatory response. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Inflammatory indicator:Procalcitonin (PCT,ng/mL) | Serum PCT levels (ng/mL) are measured at baseline, Day 3, and Day 7 as a marker of systemic inflammatory response. | Before treatment,on day 3 of treatment,on day 7 of treatment |
| Microecology:Gut Microbiota Alpha Diversity (Shannon Index) | Fecal samples (10g) will be collected at baseline, day 3, and day 7 of treatment. 16S rRNA high-throughput sequencing will be performed to analyze gut microbiota alpha diversity (Shannon index, unitless) to evaluate changes in intestinal microecological homeostasis. | Baseline, Day 3, Day 7 of treatment |
| Metabolomics analysis:Serum Target Metabolite Concentration | Peripheral blood (3mL) will be collected at baseline, day 3, and day 7 of treatment. Untargeted metabolomics will be performed to detect the concentration of target serum metabolites, with the unit of μmol/L, to evaluate changes in the body's metabolic status. | Baseline, Day 3, Day 7 of treatment |